MAPK/ERK Activation Sensitizes MKN-28 Cells to Cisplatin-Induced Apoptosis

Zhan-Guo Zhang, Yan-Hui Wu, Hui-Fang Liang, Bi-Xiang Zhang and Wan-Guang Zhang*

Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China

ABSTRACT

Cisplatin as a highly potent cytotoxic agent was widely used in the chemotherapy of gastric cancer. It kills cancer cells by inducing apoptosis. The Extracellular signal-regulated kinase (ERK) signaling pathway plays an important role in proliferation and survival. However, its roles in apoptosis vary. This study focused on the role of ERK in cisplatin-induced apoptosis in a stomach cancer cell line, MKN-28 cells. We found that cisplatin treatment substantially activated ERK, which was prevented by MEK inhibitor U0126. Transient transfection of MKN-28 cells with Constitutively Active-MEK1 (CA-MEK1) elevated cisplatin-induced apoptosis comparing with Dominant Negative-MEK1 (DN-MEK1). Cisplatin-induced ERK activation up-regulates pro-apoptotic gene BAK, whereas down-regulates anti-apoptotic gene BCL-2. Knocking down BCL-2 with siRNA sensitizes MKN-28 cells to the toxicity of cisplatin. These results suggested that (1) ERK activation is required for the cisplatin-induced apoptosis in MKN-28 cells; and (2) ERK mediates apoptosis by BCL-2.

KEYWORDS: Cisplatin; Gastric cancer; Apoptosis; ERK; BCL-2; BAK.

INTRODUCTION

Cisplatin is a highly potent cytotoxic and genotoxic agent used in the chemotherapy for various types of cancers such as gastric cancer, which is one of the most malignant cancers in China.1-5 Apoptosis is an important pathogenic mechanism in solid tumor,6 which is characterized by morphological changes such as cell shrinkage, chromatin condensation and fragmentation of DNA. Cisplatin treatment in vivo and in vitro results in apoptosis of cancer cells, which usually in dose- and time-dependent manner.

Several mechanisms are believed to mediate cisplatin-induced apoptosis. The primary mechanism of the cytotoxic effects is due to coordinative bonding between the atoms of platinum and DNA, leading to formation of intra-strand DNA cross-links, which induces apoptosis by activating p53 and cell cycle arrest.7 Previous study has been shown that Reactive Oxygen Species (ROS) generated by cisplatin increases lipid peroxidation, which alters enzymes and structural proteins, and direct the cell to an apoptotic pathway.8 Also, cisplatin-induced apoptosis could involve in the inflammatory pathway.9-11 Moreover, previous studies revealed that cisplatin induces apoptosis through a mechanism relaying on the Bax translocation into mitochondria and Caspase activation.12

Mitogen-activated protein kinases (MAPKs) are serine/threonine kinases involved in the regulation of various cellular responses, such as cell proliferation, differentiation and apoptosis. Three major mammalian MAPK subfamilies have been described: the Extracellular signal-regulated kinases (ERK), the c-Jun N-terminal Kinases (JNK), and the p38 kinases. Each MAPK is activated through a specific phosphorylation cascade. The ERK pathway plays
a major role in regulating cell growth and differentiation, being highly induced in response to growth factors and cytokines. It is also activated by some conditions of stress, particularly oxidant injury, and such circumstances is believed to confer a survival advantage to cells. Comparatively, JNK and p38 are weakly activated by growth factors, but are highly activated in response to stress signals including tumor necrosis factor, ionizing and short wave length Ultraviolet irradiation (UVC), and hyperosmotic stress. Their activation is most frequently associated with induction of apoptosis. In cisplatin treatment, ERK was activated in a variety of cell lines. While some studies showed that the ERK activation enhances survival of cisplatin-treated cells, then some other studies reported that it induces apoptosis in cisplatin exposed cells. Gastric cancer is one of the malignant cancers in China. The functional roles of ERK in cisplatin treatment of gastric cancer remain elusive. The present study sought to delineate the role of the ERK signaling in cisplatin-induced apoptosis using a gastric cancer cell line, MKN-28.

**MATERIAL AND METHODS**

**Cell Culture**

Human gastric adenocarcinoma (MKN-28) cells were obtained from the American Type Culture Collection. Cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) (Hyclone, Logan, Utah, USA) supplemented with 10% fetal bovine serum (Hyclone, Logan, Utah, USA) and 1% penicillin–streptomycin (Gibco, Grand Island, NY, USA). Cells were cultured in a 37 °C humidified incubator with a mixture of 95% air and 5% CO₂.

**Reagents**

Constitutively Active-MEK1 and Domain Negative-MEK1 was purchased from Addgene, and then sub-cloned into pCMV vector. The MEK inhibitor U0126 and JNK inhibitor SP600125 were purchased from Tocris (Bristol, UK). Immunoblotting experiments were performed with rabbit anti-caspase-3, anti-caspase-8, anti-caspase-9, anti-PARP, anti-Bid, anti-BAK, anti-Bax, anti-PUMA, anti-cytochrome c and anti-BCL-2 were from Epitomics (Burlingame, CA, USA), anti-phospho-p44/42 MAPK (p-ERK1/2) (Thr202/Tyr204), and anti-ERK1/2 antibodies were purchased from Cell Signaling Technology (Beverly, MA, USA); The Horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG polyclonal antibodies were obtained from Santa Cruz Biotechnology (Dallas, Texas, USA).

**Immunoblotting (Western Blot Assay)**

Cells were lysed in PIRA buffer (Beyongtime, China). Following boiling for 5 min, samples were separated on 10% SDS-polyacrylamide gels and then transferred to an Immobilon membrane (Millipore, MA, USA). The membranes were blocked with 5% non-fat dry milk in TBS/Tween20 (0.05% v/v) for 1 h followed by incubation at 4 °C overnight with the indicated primary antibodies. The membranes were washed three times with TBST buffer and then incubated for 1 h with HRP-conjugated anti-rabbit or -mouse secondary antibodies. Visualization of protein bands was accomplished using enhanced chemiluminescence (Thermo Scientific).

**Detection of Cell Apoptosis (Annexin V/PI)**

Cells were seeded at a density of 1.0×10⁵ cells per well in 24-well plates, cultured with different reagents for 48 h, and then harvested. The cells were washed with PBS and then stained 5 μL of Propidium Iodide (PI) for 15 min followed by 5 μL of Annexin V and at room temperature in the dark according to the manufacturer’s instructions (Nanjing Key Gen Biotech, Nanjing, China). The apoptosis rate (%) of the stained cells was analyzed using FCM. The experiments were repeated three times.

**Detection of Cell Death (Lactate Dehydrogenase Release Assay)**

Cell death was quantitatively detected based on the release of LDH by using a cytotoxicity detection kit (Roche Life Science, IN, USA) as described in manufacturer’s instruction. All the experiments were repeated three times and the average is shown in each figure.

**Analysis of Cytochrome c Release**

To assess mitochondrial cytochrome c release, cytosolic protein extracts were obtained according to instructions of a commercial cell fractionation kit (Enzo Life Sciences, Farmingdale, NY, USA). Briefly, 1 × 10⁵ cells in a dish of 10 cm in diameter were washed twice with cold PBS and then centrifuged at 600g for 5 min at 4 °C. Cells were suspended in 0.1 ml of ice-cold fractionation buffer and then incubated on ice for 10 min before being homogenized with a syringe needle. The homogenates were centrifuged at 700 g for 10 min at 4 °C, after which the supernatants were collected and centrifuged at 10,000 g for 30 min at 4 °C. The supernatant was again collected as the cytosolic fraction and analyzed for cytochrome c release by western blot assay.

**Silence BCL-2 with Smart Pool siRNA**

SMART pool: ON-TARGET plus BCL-2 siRNA and Transfection Reagent-1 were both purchased from Damarchon (Lafayette, CO, USA), Cat# L-003307-00-0005. Transfection procedure was followed the manufacturer’s instructions.

**Statistical Analysis**

All results of bar graphs are expressed as the mean ± S.D. obtained from three independent experiments in duplicate. Statistical differences were evaluated using the Student’s t-test or
ANOVA. *P* < 0.05 was considered statistically significant.

**RESULTS**

**Cisplatin Induces Apoptosis in MKN-28 Cells through the Mitochondrial Pathway**

Cisplatin treatment induces apoptosis in many different cell lines. To test the effect of apoptosis in MKN-28 cells, MKN-28 cells were treated with cisplatin in an increasing dose (0 μg/mL, 4 μg/mL, 8 μg/mL, 12 μg/mL, 16 μg/mL, and 20 μg/mL) for different time point (12 h, 24 h, 36 h). After the treatment, cells were stained by Annexin V-FITC and PI, and were examined by Flow cytometry (FCM). As shown in figure 1A, cisplatin treatment resulted in dose- and time-dependent manner in MKN-28 cells. Most cells were dead after 48 h treatment in dose 16 μg/mL and 20 μg/mL (Supplementary Figure 1). The apoptotic marker such as cleaved caspase-3 and cleavage of Poly (ADP-ribosyl) polymerase (PARP) can be detected by Western blot analysis (Figure 1B). The LDH releasing experiment also revealed that the LDH leaked from apoptotic cells after cisplatin treatment (Figure 1C). Meanwhile, the cell viability was opposite changed. Treatment of MKN-28 cells with cisplatin resulted in a time-dependent increase in release of cytochrome c from mitochondria (Figure 1D). These results suggested that cisplatin induced MNK-28 cell apoptosis via the mitochondrial pathway.

**Cisplatin Induces Apoptosis in MKN-28 Cells with the MAPK Signaling Pathway activation**

Cells were exposed in cisplatin at various time points in a dose of 20 μg/ml. The activation of MAPK pathway was then detected by Western blot, including ERK1/2 (p42/44), p38, and JNK. In the treatment, JNK was activated moderately while ERK was activated remarkably. (Figure 2) This result showed a relationship between cisplatin-mediated apoptosis and ERK signaling cascade.

**ERK activation enhanced cisplatin-induced apoptosis**

Pharmaceutical inhibition was applied to test if the...

---

**Supplementary Figure 1:** Annexin V/PI apoptosis assay used to detected apoptosis of MKN-28 cells treated with Cisplatin in different doses for 48 hours. Most cells died at 16 and 20 μg/mL concentration.
MAPK/ERK pathway involved in cisplatin-induced apoptosis. The effect of MAPK inhibitors was detected with Western blot (Figure 3A). Apoptosis assay analysis showed that cisplatin-induced apoptosis of MKN-28 cells was blocked by the MEK inhibitor U0126, but not c-Jun N-terminal Kinase (JNK) inhibitor SP600125 at the 24 hr and 36 hr. (Figure 3B). These results demonstrated that the cisplatin-induced apoptosis with MAPK pathway activation. It suggested that cisplatin-induced MKN-28 apoptosis was abolished by the MEK inhibitor U0126, but not by JNK inhibitor SP600125.

In addition, we test the role of ERK by ectopically expressing constitutively active and dominant-negative ERK mutant. Cells were transfected with pCMV-CA-MEK1 and pCMV-DN-MEK1 (Figure 3C). Highly activation of phospho-ERK was detected with Western blot after transiently transfected CA-MEK1, but not for the DN-MEK1 transfected cells. When these cells were treated with cisplatin, CA-MEK1 transfected cells presented higher activation than control group while a reduced level of ERK activation appeared in dominant-negative mutant expressing cells (Figure 3D). The apoptosis assay suggested that CA-MEK1 group acquired higher ERK1 activation and apoptosis (Figure 3E and 3F). These data indicate that ERK activation induces the cisplatin-induced MKN-28 cells apoptosis.

**Figure 2:** Cisplatin activates the MAPK/ERK signaling pathway. Immunoblot analysis of the MAPK activation within lysates generated from MKN-28 cells that were untreated or were cultured for 6 h, 12 h, 24 h, 36 h and 48 h in the presence of cisplatin (20 μg/ml).

**Figure 3:** Cisplatin-induced apoptosis was prohibited by MEK inhibitor, whereas enhanced by CA-MEK1 transfection. (A) Representative Immunoblot of MAPK activation of untreated MKN-28 cells, MKN-28 cells treated with 20 μg/ml Cisplatin, MKN-28 cells treated with 10 μM U0126 plus 20 μg/ml cisplatin, and MKN-28 cells treated with 20 μg/ml SP600125 plus 20 μg/ml cisplatin and two inhibitors combination with 20 μg/ml cisplatin for 36 h. Phospho-ERK1/2, Phospho-JNK1/2 and total protein were examined. (B) Quantitation of apoptosis used Annexin V/PI FCM assay. (C) Immunoblot assay was used to detect the ERK activation of MKN-28 cells after CA-MEK1 or DN-MEK1 transient transfection. (D) The control and transfected MKN-28 cells treated with 20 μg/ml cisplatin for 36 h, the phospho-ERK1/2 was detected by immunoblot assay. (E, F) The apoptosis of the control and transfected MKN-28 cells, which incubated with or without cisplatin, were calculated by Annexin V/PI FCM apoptosis assay (*p<0.05, **p<0.01). Each experiment was repeated for at least three times.
ERK-Mediated BCL-2 Inhibition Induces Apoptosis

To examine the relationship between ERK activation and BCL-2 family, we investigated the BCL-2 family by Western Blot. After cisplatin treatment, the BCL-2 expression level was down-regulated. Meanwhile, the BAK level was up-regulated (Figure 4A). To test if BCL-2 is the downstream transducers of the activated ERK-induced apoptosis, MKN-28 cells were transient transfected with CA-MEK. Dramatically, we found that BCL-2 was down-regulated concurrently with BAK up-regulation after CA-MEK1 transfection. The opposite result can be found after DN-MEK1 transfection (Figure 4B). This result suggested that BCL-2 and BAK are both downstream of activated ERK. Furthermore, when BCL-2 was knocked down by smart pool siRNA, cisplatin-induced apoptosis was remarkably increased (Figure 4C and 4D). Taken together, the results suggested that, with cisplatin treatment, (1) ERK activation regulate BCL-2 and BAK, (2) BCL-2 down-regulation facilitate apoptosis.

DISCUSSION

Two major distinct apoptosis pathways have been described for mammalian cells: (1) Mitochondrial independent pathway, which is recruited by the adapter molecule Fas/APO-1-associated death domain protein to death receptors upon extracellular ligand binding; (2) cytochrome c release-dependent activation of caspase-9 through Apaf-1. We did, however, observe an increase of cytochrome c in the cytoplasm of cisplatin-treated cells relative to untreated cells, suggesting that cytochrome c release is involved in cisplatin-induced apoptosis.

The MAPK pathways, including ERK, were typically studied previously. However, the roles of ERK in cancer protection are controversial. Most investigations revealed the importance of MAPK signaling pathways in regulating apoptosis during conditions of stress. But majority of the studies supported the general hypothesis that ERK activation delivers a survival signal and inhibition of ERK signaling leads to increased sensitivity of some cell lines to cisplatin. Although more often associated with survival, a pro-apoptotic function for the ERK pathway has also been suggested in several other model systems. In our study, however, we provided evidence that activation of ERK is important for the inducting cisplatin-induced apoptosis in MKN-28 cells. By modulating ERK activity, we found that both Domain-Negative MEK transfection and MEK specific inhibitor U0126 led to an inhibition of cisplatin-induced apoptosis. Meanwhile, enhancement of ERK activity by over-expressing Constitutively Active MEK in MKN-28 cells accentuated cell apoptosis. ERK activity-dependent cisplatin-induced apoptosis was not limited to MKN-28 cells, but also occurred in human lung cancer A549 cells and Hela cells.

Although several studies have shown that JNK is activated in cisplatin treatment, their role in determining survival is unclear. A number of studies have provided evidence indicating that the JNK pathway contributes to cisplatin-induced apoptosis. However, others have suggested that JNK signal-
ing is important for cell survival.\textsuperscript{11,31,34} Such differential effects observed from one study to another could indicate cell type specificity. In our own studies using MKN-28 cells, we found that JNK was indeed activated by cisplatin treatment. However, down-regulation of this pathway by JNK specific inhibitor SP600125 did not make any changes of the sensitivity to cisplatin. Thus, only ERK appears to play a major role in influencing the survival of cisplatin-treated MKN-28 cells.

How does ERK activation lead to apoptosis of cisplatin-treated cells? What are the downstream transducers involved in mediating the apoptosis? Based on previous and our study, ERK activation is necessary, but not sufficient to induce apoptosis, as TPA treatment (Supplementary Figure 2) or constitutively active-MEK over expression did not result in cell death. With cisplatin, no significant activation occurs until 6 h, but the activity remains highly elevated through the remaining time period examined (48 h).

BCL-2 is known as an anti-apoptotic BCL-2 family member, for which amplification has been associated with a more aggressive malignant phenotype and drug resistance to various categories of chemotherapeutic drugs in malignancies.\textsuperscript{35} Moreover, BCL-2 was reported as a target gene for many signaling cascades, such as Phosphatidylinositol 3 kinase (PI3K)/nuclear factor-xB (NF-xB) signaling pathway, the cyclic AMP (cAMP)/protein kinase A (PKA) cascade, MAPK cascade and so on.\textsuperscript{36,37} In this study, we found that treatment of cisplatin increased phosphorylation of ERK proteins, which intervened downstream anti-apoptosis molecular BCL-2 and up-regulation of pro-apoptosis molecular BAK in gastric cancer MKN-28 cells. With BCL-2 and BAK change, cisplatin promoted MKN-28 cells apoptosis.

Increasing amount of evidence indicated that the ERK pathway is important in malignant disease.\textsuperscript{38,39} One recent study indicated that ERK activation by TGF-beta plays a key oncogenic role in Colorectal cancer (CRC) with SMAD4 inactivation mutations. The MEK inhibitor U0126 can surprisingly reduce CT26 and liver metastasis in vivo and in vitro.\textsuperscript{40} suggesting that MEK inhibitors can be a primary approach for treatment of human malignancies. However, our findings indicated a need for caution for the generality of this therapeutic approach. On the other hand, coupled with previous studies,\textsuperscript{21,22} our findings supported a role of the ERK signaling pathway in enhancing cisplatin-induced apoptosis, further suggesting that strategies targeting activation of this cascade could be employed to enhance the therapeutic effectiveness of cisplatin. In addition, evaluation of ERK activity could be useful marker for predicting which tumors would present favorable response to cisplatin therapy.

CONFLICTS OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

We should thank all the staffs in my lab for discussing the project. This work was supported by the State Key Project on Infection Disease of China (Nos. 2012ZX10002016-004 and 2012ZX10002010-001-004). The National Natural Science Foundation of China (81202300 and 81372327).

REFERENCES

1. Villar A, Farrus B, Giner P, et al. Cisplatin alone or in combination with adriamycin in the treatment of patients with head and neck cancer relapsed after radiotherapy and/or surgery. Revista Espanola De Oncologia. 1981; 28(3): 395-412.

2. Bhuchar VK and Lanzotti VJ. High-dose cisplatin for lung cancer. Cancer Treatment Reports. 1982; 66(2): 375-376.

3. Blumenreich MS, Needles B, Yagoda A, et al. Intravesical cisplatin for superficial bladder tumors. Cancer. 1982; 50(5): 863-865.

4. Bagley CM, Jr., Rudolph RH, Rivkin SE and Yon JL, Jr. High-dose cisplatin therapy for cancer of the ovary: neurotoxicity. Annals of Internal Medicine. 1985; 102(5): 719. doi: 10.7326/0003-4819-102-5-719

5. Ky V, Hav M, Berrevoet F, et al. Cisplatin-modified de Gramont in second-line therapy for pancreatic adenocarcinoma. Pancreas. 2013; 42(7): 1138-1142. doi: 10.1097/MPA.0b013e31829a80b7

6. Ocker M and Hopfner M. Apoptosis-modulating drugs for improved cancer therapy. European Surgical Research. Europaische Chirurgische Forschung, Recherches Chirurgicales Europeennes. 2012; 48(3): 111-120. doi: 10.1159/000336875

7. Thomas JP, Lautermann J, Liedert B, Seiler F, homale J. High accumulation of platinum-DNA adducts in strial marginal cells of the cochlea is an early event in cisplatin but not carboplat-
8. Casares C, Ramirez-Camacho R, Trinidad A, et al. Reactive oxygen species in apoptosis induced by cisplatin: review of physiopathological mechanisms in animal models. European Archives of Oto-Rhino-Laryngology: Official Journal of the European Federation of Oto-Rhino-Laryngological Societies. 2012; 269(12): 2455-2459. doi: 10.1007/s00405-012-2029-0

9. Duan L, Aoyagi M, Tamaki M, et al. Sensitization of human malignant glioma cell lines to tumor necrosis factor-induced apoptosis by cisplatin. Journal of Neuro-Oncology. 2001; 52(1): 23-36. doi: 10.1023/A:1010685110862

10. Song JH, Song DK, Herlyn M, Petruk KC, Hao C. Cisplatin down-regulation of cellular Fas-associated death domain-like interleukin-1beta-converting enzyme-like inhibitory proteins to restore tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human melanoma cells. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 2003; 9(11): 4255-4266.

11. Benedetti G, Fredrikssoon L, Herpers B, et al. TNF-alpha-mediated NF-kappaB survival signaling impairment by cisplatin enhances JNK activation allowing synergistic apoptosis of renal proximal tubular cells. Biochemical Pharmacology. 2013; 85(2): 274-286. doi: 10.1016/j.bcp.2012.10.012

12. Lee RH, Song JM, Park MY, et al. Cisplatin-induced apoptosis by translocation of endogenous Bax in mouse collecting duct cells. Biochemical Pharmacology. 2001; 62(8): 1013-1023. doi: 10.1016/s0006-2952(01)00748-1

13. Osaki LH, Gama P. MAPKs and signal transduction in the control of gastrointestinal epithelial cell proliferation and differentiation. International Journal of Molecular Sciences. 2013; 14(5): 10143-10161. doi: 10.3390/ijms140510143

14. Kobayashi K, Tsukamoto I. Prolonged Jun N-terminal kinase (JNK) activation and the upregulation of p53 and p21(WAF1/CIP1) preceded apoptosis in hepatocytes after partial hepatectomy and cisplatin. Biochimica Et Biophysica Acta. 2001; 1537(1): 79-88. doi: 10.1016/s0925-4439(01)00059-x

15. Zhao Z, Wang J, Tang J, et al. JNK- and Akt-mediated Puma expression in the apoptosis of cisplatin-resistant ovarian cancer cells. The Biochemical Journal. 2012; 444(2): 291-301. doi: 10.1042/Bj20111855

16. Pereira L, Igea A, Canovas B, Dolado I, Nebreda AR. Inhibition of p38 MAPK sensitizes tumour cells to cisplatin-induced apoptosis mediated by reactive oxygen species and JNK. EMBO Molecular Medicine. 2013; 5(11): 1759-1774. doi: 10.1002/emmm.201302732

17. Wang X, Martindale JL, Holbrook NJ. Requirement for ERK activation in cisplatin-induced apoptosis. The Journal of Biological Chemistry. 2000; 275(50): 39435-39443. doi: 10.1074/jbc.m004583200

18. Choi BK, Choi CH, Oh HL, Kim YK. Role of ERK activation in cisplatin-induced apoptosis in A172 human glioma cells. Neurotoxicology. 2004; 25(6): 915-924. doi: 10.1016/j.neuro.2004.06.002

19. Schweyer S, Soruri A, Meschter O, et al. Cisplatin-induced apoptosis in human malignant testicular germ cell lines depends on MEK/ERK activation. British Journal of Cancer. 2004; 91(3): 589-598. doi: 10.1038/sj.bjc.6601919

20. Kim YK, Kim HJ, Kwon CH, et al. Role of ERK activation in cisplatin-induced apoptosis in OK renal epithelial cells. Journal of Applied Toxicology: JAT. 2005; 25(5): 374-382. doi: 10.1002/jat.1081

21. Clark JS, Faisal A, Baliga R, Nagamine Y, Arany I. Cisplatin induces apoptosis through the ERK-p66shc pathway in renal proximal tubule cells. Cancer Letters. 2010; 297(2): 165-170. doi: 10.1016/j.canlet.2010.05.007

22. Zhang W, Zhao L, Liu J, et al. Cisplatin induces platelet apoptosis through the ERK signaling pathway. Thrombosis Research. 2012; 130(1): 81-91. doi: 10.1016/j.thromres.2012.02.013

23. Fiandalo MV, Schwarze SR, Kyprianou N. Proteasomal regulation of caspase-8 in cancer cell apoptosis. Apoptosis: An International Journal on Programmed Cell Death. 2013; 18(6): 766-776. doi: 10.1007/s10495-013-0821-y

24. Zhang X, Zhao J, Zhu W, et al. Synergistic Effect of Sub-toxic-dose Cisplatin and TRAIL to Mediate Apoptosis by Down-regulating Decoy Receptor 2 and Up-regulating Caspase-8, Caspase-9 and Bax Expression on NCI-H460 and A549 Cells. Iranian Journal of Basic Medical Sciences. 2013; 16(5): 710-718.

25. Brentnall M, Rodriguez-Menocal L, De Guevara RL, Cepero E, Boise LH. Caspase-9, caspase-3 and caspase-7 have distinct roles during intrinsic apoptosis. BMC Cell Biology. 2013; 14: 32. doi: 10.1186/1471-2121-14-32

26. Zhang L, Sang H, Liu Y, Li J. Manganese activates caspase-9-dependent apoptosis in human bronchial epithelial cells. Human & Experimental Toxicology. 2013; 32(11): 1155-1163. doi: 10.1177/0960327112470272

27. Imao T, Nagata S. Apaf-1- and Caspase-8-independent apoptosis. Cell Death and Differentiation. 2013; 20(2): 343-352. doi: 10.1038/cdd.2012.149

28. Zhao Y, Zhao X, Yang B, Neuzil J, Wu K. alpha-Tocopheryl succinate-induced apoptosis in human gastric cancer cells is
modulated by ERK1/2 and c-Jun N-terminal kinase in a biphasic manner. Cancer Letters. 2007; 247(2): 345-352. doi: 10.1016/j.canlet.2006.05.015

29. Lin MW, Lin AS, Wu DC, et al. Euphol from Euphorbia tirucalli selectively inhibits human gastric cancer cell growth through the induction of ERK1/2-mediated apoptosis. Food and Chemical Toxicology: an International Journal Published for the British Industrial Biological Research Association. 2012; 50(12): 4333-4339. doi: 10.1016/j.fct.2012.05.029

30. Prasad CP, Chaurasiya SK, Axelsson L, Andersson T. WNT-5A triggers Cdc42 activation leading to an ERK1/2 dependent decrease in MMP9 activity and invasive migration of breast cancer cells. Molecular Oncology. 2013; 7(5): 870-883. doi: 10.1016/j.molonc.2013.04.005

31. Zheng GH, Liu CM, Sun JM, Feng ZJ, Cheng C. Nickel-induced oxidative stress and apoptosis in Carassius auratus liver by JNK pathway. Aquatic Toxicology. 2014; 147: 105-111. doi: 10.1016/j.aquatox.2013.12.015

32. Guo L, Chen R, Ma N, et al. Phosphorylation of eIF2alpha Suppresses Cisplatin-Induced A549 Cell Apoptosis via p38 Inhibition. Cancer Biotherapy & Radiopharmaceuticals. 2013; 28(4): 268-273. doi: 10.1089/cbr.2012.1340

33. Svensson C, Part K, Kunnis-Beres K, et al. Pro-survival effects of JNK and p38 MAPK pathways in LPS-induced activation of BV-2 cells. Biochemical and Biophysical Research Communications. 2011; 406(3): 488-492. doi: 10.1016/j.bbrc.2011.02.083

34. Ma J, Zhang L, Han W, et al. Activation of JNK/c-Jun is required for the proliferation, survival, and angiogenesis induced by EET in pulmonary artery endothelial cells. Journal of Lipid Research. 2012; 53(6): 1093-1105. doi: 10.1194/jlr.M024398

35. Zheng Y, Zhou M, Ye A, et al. The conformation change of Bcl-2 is involved in arsenic trioxide-induced apoptosis and inhibition of proliferation in SGC7901 human gastric cancer cells. World journal of surgical oncology. 2010; 8: 31. doi: 10.1186/1477-7819-8-31

36. Chen G, Wang Y, Li M, et al. Curcumol induces HSC-T6 cell death through suppression of Bcl-2: Involvement of PI3K and NF-kappaB pathways. European Journal of Pharmaceutical Sciences: Official Journal of the European Federation for Pharmaceutical Sciences. 2014; 65C: 21-28. doi: 10.1016/j.ejps.2014.09.001

37. Kim SJ, Nian C, Widemaier S, McIntosh CH. Glucose-dependent insulinotropic polypeptide-mediated up-regulation of beta-cell antiapoptotic Bcl-2 gene expression is coordinated by cyclic AMP (cAMP) response element binding protein (CREB) and cAMP-responsive CREB coactivator 2. Molecular and Cellular Biology. 2008; 28(5): 1644-1656. doi: 10.1128/mcb.00325-07

38. Ding Q, Miyazaki Y, Tsukasa K, et al. CD133 facilitates epithelial-mesenchymal transition through interaction with the ERK pathway in pancreatic cancer metastasis. Molecular Cancer. 2014; 13(1): 15. doi: 10.1186/1476-4598-13-15

39. Ochi N, Takigawa N, Harada D, et al. Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancer. Experimental Cell Research. 2014; 322(1): 168-177. doi: 10.1016/j.yexcr.2014.01.007

40. Ai X, Wu Y, Zhang W, et al. Targeting the ERK pathway reduces liver metastasis of Smad4-inactivated colorectal cancer. Cancer Biology & Therapy. 2013; 14(11): 1059-1067. doi: 10.4161/cbt.26427